Pfizer eyes generic biologics market

07 March, 2006

No. 1 drugmaker Pfizer Inc. said on Tuesday that it is preparing to enter into the emerging market of generic biotech drugs, also known as biologics. According to Vice Chairman David Shedlarz, Pfizer will be evaluating its biologics capacity in the second half of the year to determine whether it will want to build additional facilities in order to enter the generic biologics arena.

Biologics manufacturing requires a large amount of capacity and the company is looking to leverage its capacity. Generic drugs are becoming very popular nowadays as they're equally effective but come at a much lower price. Erectile dysfunction generic drugs such as generic Viagra and generic Cialis are also becoming very popular nowadays due to their efficacy and cheaper price.

To read more, Visit:
http://www.iii.co.uk/news/?type=afxnews&articleid=5573434&subject=companies&action=article